As NSCLC accounts for more than 84% of all lung cancers, the treatment of ALK-p NSCLC with CNS metastases is becoming increasingly important as advances in lung cancer treatment ensure prolonged survival [5,15,17]. This evidence concerns the gene ALK and lung cancer.